TVTX Q3 2021 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M+33.4% YoY

Gross Profit

$67M97.7% margin

Operating Income

-$32M-46.5% margin

Net Income

-$36M-52.2% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+24.9%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$32M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$775M

Total Liabilities

$468M

Stockholders' Equity

$307M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$51M	+33.4%
Gross Profit	$67M	$50M	+33.4%
Operating Income	-$32M	-$19M	-63.2%
Net Income	-$36M	-$23M	-58.1%

Revenue Segments

Product

$54M50%

Tiopronin Products

$30M28%

Bile Acid Products

$24M22%